MARKET

VNRX

VNRX

VOLITIONRX
AMEX

Real-time Quotes | Nasdaq Last Sale

3.410
+0.400
+13.29%
Closed 16:00 05/14 EDT
OPEN
3.050
PREV CLOSE
3.010
HIGH
3.440
LOW
3.010
VOLUME
227.01K
TURNOVER
--
52 WEEK HIGH
6.67
52 WEEK LOW
2.780
MARKET CAP
180.36M
P/E (TTM)
-7.4846
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 3d ago
VolitionRX Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 12, 2021 / VolitionRX Ltd. (NYSE:VNRX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 8:00 AM Eastern Time.
ACCESSWIRE · 3d ago
8-K: VOLITIONRX LTD
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
VolitionRX EPS in-line, beats on revenue
VolitionRX (VNRX): Q1 GAAP EPS of -$0.12 in-line.Revenue of $25.53K beats by $0.02M vs. $544K year ago.Press Release
Seekingalpha · 4d ago
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
PR Newswire · 4d ago
10-Q: VOLITIONRX LTD
Edgar Online - (EDG = 10Q, 10K) · 4d ago
Earnings Scheduled For May 11, 2021
  Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter.
Benzinga · 4d ago
Diamond Equity Research Emerging Growth Invitational Spring 2021 Virtual Conference
Our conferences are open to both institutional and retail investors, allowing all investors to obtain meaningful access to management teams" stated Hunter Diamond, CFA the CEO of Diamond Equity Research.Investors can register at https://www.
ACCESSWIRE · 05/06 13:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VNRX. Analyze the recent business situations of VOLITIONRX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VNRX stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 24
Institutional Holdings: 3.02M
% Owned: 5.71%
Shares Outstanding: 52.89M
TypeInstitutionsShares
Increased
9
101.54K
New
1
802
Decreased
4
84.17K
Sold Out
2
35.57K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.22%
Healthcare Equipment & Supplies
+1.17%
Key Executives
Chairman/Executive Director
Martin Faulkes
Chief Executive Officer/President/Director
Cameron Reynolds
Chief Financial Officer/Treasurer
Terig Hughes
Corporate Executive
Salvatore Butera
Corporate Executive
Jasmine Kway
Chief Operating Officer
Gaetan Michel
Chief Technology Officer
Mark Eccleston
Chief Scientific Officer
Jacob Micallef
Other
Gael Forterre
Other
Jason Terrell
Secretary
Rodney Rootsaert
Independent Director
Phillip Barnes
Independent Director
Richard Brudnick
Independent Director
Alan Colman
Independent Director
Edward Futcher
Independent Director
Guy Innes
Independent Director
Kim Nguyen
No Data
About VNRX
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.

Webull offers kinds of VolitionRX Ltd stock information, including AMEX:VNRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNRX stock methods without spending real money on the virtual paper trading platform.